• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CCXI

CCXI

Churchill Capital Corp XI

NASDAQFinancial ServicesFinancial - ConglomeratesUS

USD10.23

+0.01 (+0.15%)

Rating:C+

Company Profile

CEO

Michael S. Klein

IPO Date

2026-02-09

Sector

Financial Services

Industry

Financial - Conglomerates

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.20

Prev. Close

$10.22

Day Low

$10.20

Day High

$10.23

52W Low

$10.07

52W High

$11.00

Market Cap

$0.43B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

13.1%

Avg Negative

31.8%

Avg Neutral

55.1%

News Feed

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Seeking Alpha·8/24/2021·↑ positive

ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down

Zacks Investment Research·8/10/2021·↓ negative

ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/9/2021·↓ negative

ChemoCentryx: Q2 Earnings Insights

Benzinga·8/9/2021·↓ negative

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

GlobeNewsWire·8/4/2021·↑ positive

ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021

GlobeNewsWire·8/2/2021·↓ negative

ChemoCentryx: CRL Less Likely

Seeking Alpha·7/25/2021·↑ positive

Is Now the Time to Buy ChemoCentryx Stock?

The Motley Fool·7/10/2021·↓ negative

ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan

Zacks Investment Research·7/7/2021·↑ positive

(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?

PRNewsWire·7/7/2021·↓ negative